FDA raises questions about efficacy of pain medication tamper-proofing
NEW YORK Questions have arisen as to whether a pill by Pain Therapeutics and King Pharmaceuticals is resistant to tampering.
A memo by the Food and Drug Administration Monday concerns the drug Remoxy, a formulation of oxycodone that uses liquid capsule drug-delivery technology designed to prevent misuse of the drug. Some people have abused oxycodone tablets by crushing them, dissolving it in water and then injecting it for its opiate-like effects.
The FDA’s memo said that Pain Therapeutics did not sufficiently conduct long-term tests of Remoxy to determine whether the oxycodone could be extracted and diverted, though Pain Therapeutics disputes that claim.
Jewel-Osco extends Prescription Plus offerings for more customers to get flu shots
ITASCA, Ill. A retail pharmacy chain is reminding patients to use their prescription medications properly and get vaccinated despite the difficult economy.
Jewel-Osco Pharmacy will extend its Prescription Plus Rewards Programs through Jan. 31, allowing frequent pharmacy customers to save money on groceries. The program offers customers a 10 percent discount coupon for every five prescriptions they fill at the pharmacy using a discount card.
“As pharmacists, our foremost concern is helping our patients comply with their prescribed medication therapies,” Jewel-Osco vice president for pharmacy operations Tom Rousonelos said. “We’re extending the length of Prescription Plus in response to a real need our pharmacy customers tell us they have for the continuous opportunities to reduce their grocery bills through this program.”
FDA approves Aurobindo’s generic version of Zoloft
ROCKVILLE, Md. The Food and Drug Administration has approved Aurobindo’s application for sertraline hydrochloride oral concentrate, FDA records show.
The drug is a generic version of Pfizer’s antidepressant Zoloft. Roxane and Ranbaxy also offer generic versions.
The FDA approved sertraline hydrochloride tablets from Aurobindo in February 2007. The oral concentrate formulation received approval on Oct. 31.